Actively Recruiting
Study Evaluating SPY072 with Standard Care in Adults with Moderate to Severe Hidradenitis Suppurativa
Led by Spyre Therapeutics, Inc. · Updated on 2026-10-19
150
Participants Needed
34
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the investigational drug SPY072 in adults aged 18 to 75 with moderate to severe hidradenitis suppurativa HS who are also receiving advanced standard of care treatment. This Phase 2, multicenter, randomized, double-blind study aims to assess whether SPY072 can improve symptoms of HS compared to placebo while continuing standard treatment. The study will also monitor safety and how long any treatment effects last. Participants will be randomly assigned to receive either SPY072 or a matching placebo, both given as subcutaneous injections, alongside bimekizumab, an advanced standard of care medication. The treatment period lasts 16 weeks, after which participants enter a follow-up phase to evaluate ongoing safety and durability of response. During the study, participants will undergo regular assessments including clinical evaluations of HS lesions and response to treatment. Researchers will measure outcomes such as the percentage of participants achieving a significant clinical response at Week 16. Safety monitoring will continue up to 52 weeks, and participants progress will be closely tracked throughout the treatment and follow-up periods, which may last until the study ends in mid-2028.
CONDITIONS
Brief Title
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Research Team
S
SKYLIGHT Trial Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here